Imatinib Mesylate.
Recent Results Cancer Res
; 212: 1-27, 2018.
Article
in En
| MEDLINE
| ID: mdl-30069623
Full text:
1
Database:
MEDLINE
Main subject:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Gastrointestinal Stromal Tumors
/
Protein Kinase Inhibitors
/
Imatinib Mesylate
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Recent Results Cancer Res
Year:
2018
Type:
Article
Affiliation country:
Germany